New radiation schedule aims to cut side effects for thymic cancer patients

NCT ID NCT06189183

Ongoing Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with stage II or III thymoma or thymic carcinoma are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (hypofractionated radiotherapy)
What this could lead to: If successful, this could offer a more convenient and less toxic radiation option after surgery for thymic tumors, potentially improving disease control.
What could go wrong: This is a small, single-center phase 2 trial with no control group, so results may not be definitive. Radiation can still cause side effects like lung or heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma thymus neoplasm Thymus Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYMUS NEOPLASMS

Contacts and locations

Locations

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.